Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday.

According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “

A number of other brokerages also recently weighed in on ATNM. Maxim Group reiterated a “buy” rating and set a $3.00 price target on shares of Actinium Pharmaceuticals in a report on Wednesday, October 25th. Roth Capital reiterated a “buy” rating and set a $6.00 price target on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. Finally, B. Riley initiated coverage on Actinium Pharmaceuticals in a report on Wednesday, December 6th. They set a “buy” rating and a $2.75 price target on the stock. Five equities research analysts have rated the stock with a buy rating, Actinium Pharmaceuticals has an average rating of “Buy” and an average price target of $3.75.

Shares of Actinium Pharmaceuticals (ATNM) opened at $0.75 on Monday. The stock has a market capitalization of $59.22, a price-to-earnings ratio of -1.60 and a beta of 41.30. Actinium Pharmaceuticals has a 52-week low of $0.54 and a 52-week high of $1.72.

WARNING: This news story was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://theolympiareport.com/2018/01/17/actinium-pharmaceuticals-atnm-downgraded-by-zacks-investment-research-to-hold.html.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Get a free copy of the Zacks research report on Actinium Pharmaceuticals (ATNM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.